突变钙网蛋白作为TpoR的致癌性异常伴侣蛋白及运输缺陷型致病TpoR突变体的伴侣蛋白
在骨髓增殖性肿瘤中常见的CALR第9外显子+1移码突变产生富含正电荷氨基酸的新C端序列,使突变CALR获得异常伴侣蛋白活性,可稳定TpoR二聚体并将其及部分运输缺陷型TpoR突变体运送至细胞表面,该功能为致癌转化所必需。
要点
- 突变CALR通过异常伴侣蛋白活性稳定TpoR二聚体并促进其及运输缺陷型突变体抵达细胞表面。
- 该伴侣蛋白功能为突变CALR致癌转化所绝对必需。
- 突变CALR可挽救TpoR/MPL R102P等致病突变体的运输与功能,并克服内质网滞留信号。
核心结论
- 突变CALR是TpoR及运输缺陷型TpoR突变体的异常伴侣蛋白,该功能为致癌效应所必需。
研究设计与样本
- 本文为分子机制研究,未报告样本量。
主要发现
- 突变CALR新C端序列赋予其异常伴侣蛋白活性,稳定TpoR二聚体状态并将TpoR及其突变体以本应无法通过质量控制的形态运送至细胞表面。
- 突变CALR通过分泌途径决定部分未成熟TpoR的运输,因其保护N117连接聚糖免于在高尔基体中进一步加工。
- TpoR/MPL R102P等工程化或疾病相关TpoR突变体可被突变CALR挽救运输与功能,突变CALR亦可克服TpoR上的内质网滞留信号。
- 突变CALR除需TpoR的N-糖基化外,还需TpoR胞外域中的疏水斑块以诱导TpoR热稳定性及初始细胞内激活,而完全激活需TpoR定位于细胞表面。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Calreticulin (CALR) +1 frameshift mutations in exon 9 are prevalent in myeloproliferative neoplasms. Mutant CALRs possess a new C-terminal sequence rich in positively charged amino acids, leading to activation of the thrombopoietin receptor (TpoR/MPL). We show that the new sequence endows the mutant CALR with rogue chaperone activity, stabilizing a dimeric state and transporting TpoR and mutants thereof to the cell surface in states that would not pass quality control; this function is absolutely required for oncogenic transformation. Mutant CALRs determine traffic via the secretory pathway of partially immature TpoR, as they protect N117-linked glycans from further processing in the Golgi apparatus. A number of engineered or disease-associated TpoRs such as TpoR/MPL R102P, which causes congenital thrombocytopenia, are rescued for traffic and function by mutant CALRs, which can also overcome endoplasmic reticulum retention signals on TpoR. In addition to requiring N-glycosylation of TpoR, mutant CALRs require a hydrophobic patch located in the extracellular domain of TpoR to induce TpoR thermal stability and initial intracellular activation, whereas full activation requires cell surface localization of TpoR. Thus, mutant CALRs are rogue chaperones for TpoR and traffic-defective TpoR mutants, a function required for the oncogenic effects.
引用
- Pecquet C, Chachoua I, Roy A, et al. Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. Blood. 2019. PMID: 30902807. doi:10.1182/blood-2018-09-874578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。